Transcode Therapeutics, Inc.
RNAZ· Nasdaq
RNAZTranscode Therapeutics, Inc.
Filed May 16, 2022 · 10-Q · 46 days after period end · 0001104659-22-060806
| Metric | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|
| Net Income | -$3.47M | -$4.49M | -$41.26K |
| EPS Diluted | -$0.27 | -$0.97 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Transcode Therapeutics, Inc. · CIK 1829635 · Engraved from SEC EDGAR
ended Mar 31, 2022 · filed May 16, 2022 · 46 d after period end
